ThetaPal ThetaPal

Manufacturing / Pharmaceutical Preparations

ACADIA PHARMACEUTICALS INC

ACAD

$27.32

+$1.54 (+6.01%)

Price as of Aug 5, 2026 00:01 UTC

3.5 B

Market Cap (Mid Cap)

39%

IV Rank

59.3%

Implied Volatility

Nov 04

Next Earnings

Technical Signals as of Aug 3
Bullish
5 of 7

Trend

  • Above 20-day average $25.38
  • Above 50-day average $24.28
  • Above 200-day average $23.69 ยท +8.1%
  • Moving averages stacked 20 > 50 > 200

Momentum

  • Golden cross (50/200) 12d ago
  • Momentum cross (20/50) 25d ago

Volume

  • Below-average volume 1.0x avg

Price & Trend

Daily candles with EMA 20, SMA 50. Drag to zoom.

Options Activity & Greeks

Implied volatility, flow, and dealer positioning from the options market.

Put/Call Ratio

0.00

Bullish skew

Implied Volatility

59.3%

1% percentile

IV vs Realized

Options rich

20d HV 30.4%

Options Heat Map

Delta-risk grid for ACAD options across strikes and expirations. Hover any cell for full Greeks.

Loading option chain data...

Insider Trades

0 buys 26 sells
Date Insider Title Type Shares Value
May 04, 2026 Schneyer Mark C. Sell 3,506 $76,396
May 04, 2026 Kihara James Sell 1,332 $29,024
May 01, 2026 Schneyer Mark C. Exercise 6,815 $0
May 01, 2026 Schneyer Mark C. Exercise 6,815 $0
May 01, 2026 Kihara James Exercise 2,596 $0
May 01, 2026 Kihara James Exercise 2,596 $0
Apr 07, 2026 Schneyer Mark C. Sell 2,709 $60,140
Apr 07, 2026 Kihara James Sell 1,030 $22,866
Apr 05, 2026 Schneyer Mark C. Exercise 5,276 $0
Apr 05, 2026 Schneyer Mark C. Exercise 5,276 $0

Politician Trades in ACAD

Date Politician Party Type Amount
Jun 16, 2022 Chris Jacobs R Sale $1K-$15K

Earnings History

Date Quarter EPS Est. EPS Actual Surprise Result
Aug 04, 2026 Q2 2026 $0.06
Mar 31, 2026 Q1 2026 $0.06 $0.02 -68.4% Miss
Dec 31, 2025 Q4 2025 $0.14 $1.60 +1044.5% Beat
Sep 30, 2025 Q3 2025 $0.15 $0.42 +178.1% Beat
Jun 30, 2025 Q2 2025 $0.14 $0.16 +14.4% Beat
Mar 31, 2025 Q1 2025 $0.11 $0.11 -3.2% Miss

Track ACAD with ThetaPal

Get insider trade alerts, AI portfolio analysis, and options roll recommendations for ACAD and your entire portfolio.